182 related articles for article (PubMed ID: 12626661)
1. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.
Proudfoot JM; Croft KD; Puddey IB; Beilin LJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):846-53. PubMed ID: 12626661
[TBL] [Abstract][Full Text] [Related]
2. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis.
Wolf G; Schneider A; Helmchen U; Stahl RA
Exp Nephrol; 1998; 6(2):112-20. PubMed ID: 9567217
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.
Dol F; Martin G; Staels B; Mares AM; Cazaubon C; Nisato D; Bidouard JP; Janiak P; Schaeffer P; Herbert JM
J Cardiovasc Pharmacol; 2001 Sep; 38(3):395-405. PubMed ID: 11486244
[TBL] [Abstract][Full Text] [Related]
4. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
[TBL] [Abstract][Full Text] [Related]
5. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
6. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the AT1 angiotensin II receptor expressed in guinea pig liver.
García-Sáinz JA; Martínez-Alfaro M; Romero-Avila MT; González-Espinosa C
J Endocrinol; 1997 Jul; 154(1):133-8. PubMed ID: 9246947
[TBL] [Abstract][Full Text] [Related]
9. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G
Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100
[TBL] [Abstract][Full Text] [Related]
10. Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits.
Sanz M; Ganado P; Tejerina T
Eur J Pharmacol; 2002 May; 442(1-2):99-106. PubMed ID: 12020687
[TBL] [Abstract][Full Text] [Related]
11. Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.
Nap A; Balt JC; Pfaffendorf M; Van Zwieten PA
J Hypertens; 2002 Sep; 20(9):1821-8. PubMed ID: 12195125
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated paf (LA-paf) was found in washed human platelets and monocyte/macrophage-like U937 cells.
Korth R; Zimmermann K; Richter WO
Chem Phys Lipids; 1994 Apr; 70(2):109-19. PubMed ID: 8033283
[TBL] [Abstract][Full Text] [Related]
14. PAF effects on MCP-1 and IL-6 secretion in U-937 monocytes in comparison with oxLDL and IL-1β effects.
Verouti SN; Fragopoulou E; Karantonis HC; Dimitriou AA; Tselepis AD; Antonopoulou S; Nomikos T; Demopoulos CA
Atherosclerosis; 2011 Dec; 219(2):519-25. PubMed ID: 21920519
[TBL] [Abstract][Full Text] [Related]
15. Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan.
Martin G; Dol F; Marés AM; Berezowski V; Staels B; Hum DW; Schaeffer P; Herbert JM
J Cardiovasc Pharmacol; 2004 Feb; 43(2):191-9. PubMed ID: 14716205
[TBL] [Abstract][Full Text] [Related]
16. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
Vauquelin G; Morsing P; Fierens FL; De Backer JP; Vanderheyden PM
Biochem Pharmacol; 2001 Feb; 61(3):277-84. PubMed ID: 11172731
[TBL] [Abstract][Full Text] [Related]
17. A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects.
Fujino M; Miura S; Kiya Y; Tominaga Y; Matsuo Y; Karnik SS; Saku K
Hypertens Res; 2010 Oct; 33(10):1044-52. PubMed ID: 20668453
[TBL] [Abstract][Full Text] [Related]
18. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
19. Activation of PAF receptor by oxidised LDL in human monocytes stimulates chemokine releases but not urokinase-type plasminogen activator expression.
Beaudeux JL; Said T; Ninio E; Ganné F; Soria J; Delattre J; Soria C; Legrand A; Peynet J
Clin Chim Acta; 2004 Jun; 344(1-2):163-71. PubMed ID: 15149885
[TBL] [Abstract][Full Text] [Related]
20. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
